Summary
Rhythm conversion in patients with post-thyrotoxic atrial fibrillation (AF) has been performed with disopyramide in order to evaluate the conversion rate and to test its effect on the maintenance of sinus rhythm after cardioversion.
The duration of AF ranged from 9 to 122 months (mean 31.8 months). Of 81 patients, 12 (15%) with relatively short duration AF were converted to sinus rhythm with disopyramide. The remaining 69 patients required DC cardioversion, which restored sinus rhythm in 58 patients. The 58 DC-converted patients were divided into two groups: a disopyramide group (D group) and a non-disopyramide group (non-D group). The D group received disopyramide 300 mg per day for 3 months after DC cardioversion and the non-D group did not receive anti-arrhythmic drugs. During the early observation period, only one patient relapsed in the D group into AF, but 5 successive patients in the non-D group reverted to AF, forcing discontinuation of the non-D protocol. A second DC cardioversion performed on 3 of those 5 patients was followed by maintenance therapy with disopyramide 300 mg per day, and they remained in sinus rhythm. With the inclusion of those three subjects, sinus rhythm was still present in 44 of the total of 58 patients converted by DC (76%) at the time of follow-up (64 months).
Thus, disopyramide was effective in rhythm conversion and it was essential for the maintenance of sinus rhythm after cardioversion in patients with post-thyrotoxic AF.
Similar content being viewed by others
References
Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K (1982) Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 72: 903–906
Nakazawa HK, Handa S, Nakamura Y, Oyanagi H, Hasegawa M, Ishikawa N, Ozaki O, Ito K (1987) High maintenance rate of sinus rhythm after cardioversion in post-thyrotoxic chronic atrial fibrillation. Int J Cardiol 16: 47–55
Morris DC, Hurst JW (1980) Atrial fibrillation. In: Current Problems in Cardiology. Year Book Medicine, Chicago
Zipes DP (1984) Management of cardiac arrhythmias. In: Braunwald E (ed) Heart disease 2nd ed. Saunders, Philadelphia
Becker DV (1984) Choice of therapy for Graves' hyperthyroidism. N Engl J Med 311: 464–466
Heel RC, Brogden RN, Speight TM, Avery GS (1978) Disopyramide: A review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias. Drugs 15: 331–368
Campbell RWF (1982) Drug prophylaxis of atrial fibrillation. In: Kulbertus HE, Olsson SB, Schlepper M (eds) Atrial fibrillation. Haessle, Maelndal
McCarthy C, Varghese PJ, Barritt DW (1969) Prognosis of atrial arrhythmias treated by electrical counter shock therapy. A three-year follow-up. Br Heart J 31: 496–500
Haertel G, Louhija A, Konttinen A (1974) Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clin Pharmacol Ther 15: 551–555
Karlson BW, Torstensson I, Abjorn C, Jansson S-O, Peterson L-E (1988) Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 9: 284–290
Boissel JP, Wolf E, Gillet J, Soubrane A, Cavallaro A, Mazoyer G, Delahaye JP (1981) Controlled trial of long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. Eur Heart J 2: 49–55
Lundstrom T, Ryden L (1988) Chronic atrial fibrillation. Long-term results of direct current conversion. Acta Med Scand 223: 53–59
Bauman JL, Gallastegui J, Strasberg B, Swiryn S, Hoff J, Welch WJ, Bauernfeind RA (1986) Long-term therapy with disopyramide phosphate: Side effects and effectiveness. Am Heart J 111: 654–660
Beck OA, Gunther R, Hochrein H (1983) Cardioversion of chronic atrial fibrillation and flutter with disopyramide. Med Klin 78: 209–212
Luoma PV, Kujala PA, Juustila HJ, Takkunen JT (1978) Efficacy of intravenous disopyramide in the termination of supraventricular arrhythmias. J Clin Pharmacol 18: 293–301
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakazawa, H., Ishikawa, N., Noh, J. et al. Efficacy of disopyramide in conversion and prophylaxis of post-thyrotoxic atrial fibrillation. Eur J Clin Pharmacol 40, 215–219 (1991). https://doi.org/10.1007/BF00315198
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315198